Loading…
Reported covered position: Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel,House E&C Ctme Health Subcommittee
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
STRYKER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and advocacy with regard to regulations and legislation that could impact the medical device industry generally, and Stryker Corporation specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RECESS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Source: Senate LDA
| GLAXOSMITHKLINE, INC. |
| 36 |
| 2018–2026 |
| WALGREEN CO | 36 | 2018–2026 |
| EDWARDS LIFESCIENCES LLC | 35 | 2018–2026 |
| PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 35 | 2018–2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 35 | 2018–2026 |
| SENIOR CARE PHARMACY COALITION | 35 | 2018–2026 |
| ABIOMED INC | 31 | 2018–2025 |
| BAYER CORPORATION | 31 | 2019–2026 |
| PTC THERAPEUTICS | 29 | 2019–2026 |
| RECESS | 26 | 2020–2026 |
| STRYKER CORPORATION | 25 | 2020–2026 |
| ALKERMES, INC. | 23 | 2017–2026 |
| PFIZER, INC. | 23 | 2021–2026 |
| ALLIANCE FOR REGENERATIVE MEDICINE | 21 | 2022–2026 |
| HORIZON PHARMA | 21 | 2019–2023 |
| BAUDAX BIO, INC. (FORMERLY KNOWN AS RECRO PHARMA, INC.) | 18 | 2019–2022 |
| NATIONAL RESILIENCE, INC. | 18 | 2020–2024 |
| THE ASSISTANCE FUND | 18 | 2021–2024 |
| NOVARTIS | 17 | 2023–2026 |
| Zogenix, Inc. | 17 | 2018–2022 |
| BIOMARIN PHARMACEUTICAL INC. | 16 | 2023–2026 |
| IMPOSSIBLE FOODS INC. | 15 | 2019–2022 |
| SIEMENS HEALTHINEERS | 15 | 2019–2023 |
| CHARLES RIVER LABORATORIES | 14 | 2022–2025 |
| MATRIX MEDICAL NETWORK | 14 | 2020–2023 |
| AKEBIA THERAPEUTICS, INC. | 13 | 2020–2023 |
| EPIGENOMICS INC. | 13 | 2018–2021 |
| LOCKTON MANAGEMENT, LLC | 13 | 2018–2021 |
| AMARIN PHARM INC. | 12 | 2019–2021 |
| NEKTAR THERAPEUTICS | 12 | 2019–2022 |
| CARDINAL HEALTH | 11 | 2018–2026 |
| DISPOSERX, INC. | 11 | 2019–2021 |
| PROLACTA BIOSCIENCE, INC. | 11 | 2024–2026 |
| FLEXION THERAPEUTICS, INC. | 10 | 2017–2019 |
| FORS MARSH GROUP | 10 | 2025–2026 |
| MERCK & CO., INC. | 10 | 2017–2020 |
| Alnylam Pharmaceuticals, Inc. | 9 | 2017–2019 |
| CELGENE CORPORATION | 9 | 2017–2019 |
| LYNDRA THERAPEUTICS | 9 | 2020–2022 |
| Vaxcyte, Inc. | 9 | 2024–2026 |
| BECTON, DICKINSON AND COMPANY | 8 | 2025–2026 |
| EVERYONE MEDICINES | 8 | 2024–2025 |
| THE PROCTER & GAMBLE COMPANY | 8 | 2025–2026 |
| BIOMERIEUX, INC. | 7 | 2024–2025 |
| ELI LILLY & CO INC | 7 | 2018–2019 |
| AVANIR PHARMACEUTICALS, INC. | 6 | 2018–2019 |
| HEARTLAND FOOD PRODUCTS GROUP | 6 | 2025–2026 |
| Karyopharm Therapeutics Inc. | 6 | 2018–2019 |
| WK KELLOGG CO (FKA KELLOGG COMPANY) | 6 | 2025–2026 |
| ACCUMULUS SYNERGY, INC. | 5 | 2025 |
| Altimmune, Inc. | 5 | 2020–2021 |
| BLUEBIRD BIO | 5 | 2019–2020 |
| BREAKTHROUGH T1D (F/K/A JDRF) | 5 | 2025–2026 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | 5 | 2025–2026 |
| KRAFT HEINZ COMPANY | 5 | 2025–2026 |
| THE JEL SERT COMPANY | 5 | 2019 |
| TRIO HEALTH REGULATORY ADVISORY GROUP, LLC | 5 | 2021 |
| ANCESTRY | 4 | 2019–2020 |
| DELCATH SYSTEMS, INC. | 4 | 2026 |
| EIGER BIOPHARMACEUTICALS, INC. | 4 | 2020–2021 |
| NJOY, LLC | 4 | 2019 |
| NUVATION BIO INC. | 4 | 2026 |
| REGENERON PHARMACEUTICALS, INC. | 4 | 2025–2026 |
| SANOFI US SERVICES INC | 4 | 2018 |
| AMERICAN BEVERAGE ASSOCIATION | 3 | 2026 |
| APPLIED BIOLOGICS | 3 | 2026 |
| DEXCOM | 3 | 2026 |
| DIGNITY AND WELLNESS PATIENT SOLUTIONS, LLC | 3 | 2025 |
| GILEAD SCIENCES, INC. | 3 | 2017–2018 |
| GLOBAL KRATOM COALITION | 3 | 2025 |
| MEDICOM GROUP | 3 | 2020 |
| ORCA BIO | 3 | 2026 |
| UNILEVER | 3 | 2026 |
| GENENTECH INC | 2 | 2017–2018 |
| PEPSICO, INC. | 2 | 2026 |
| SARGENTO FOODS INC. | 2 | 2026 |
| SOBI NORTH AMERICA | 2 | 2019 |
| ANHEUSER-BUSCH COMPANIES | 1 | 2018 |
| FRESENIUS MEDICAL CARE | 1 | 2026 |
| OAK STREET HEALTH D/B/A CVS HEALTH | 1 | 2021 |
| UNDIAGNOSED DISEASE NETWORK FOUNDATION | 1 | 2024 |
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031 Preserving Patient Access to Long-Term Care Pharmacies Act
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632 - Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund; S.1574 - Long-Term Care Pharmacy Definition Act of 2021
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry; S.1574 / H.R.5632- Long-Term Care Pharmacy Definition Act of 2021.
Long-Term Care Pharmacy Definition Act of 2021
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund; S.1574 - Long-Term Care Pharmacy Definition Act of 2021
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, including S413, HR1316, HR1038; Congressional consideration of COVID relief packages
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Federal Labor-Management Partnership Act of 2019
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, including S413, HR1316, HR1038; Congressional consideration of COVID relief packages
Federal Labor-Management Partnership Act of 2019
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
Federal Labor-Management Partnership Act of 2019
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Federal Labor-Management Partnership Act of 2019
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and HR 8177 - RAISE Act.
Behavioral Health Crisis Response Improvements Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
Behavioral Health Crisis Response Improvements Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Behavioral Health Crisis Response Improvements Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038; Congressional consideration of COVID relief packages; CARES Act Provider Relief Fund
Behavioral Health Crisis Response Improvements Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, including S413, HR1316, HR1038; Congressional consideration of COVID relief packages
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
To require the Treasury to take a more prominent role in coordinating AML/CFT policy and examinations across the Government, and for other purposes.
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Federal Labor-Management Partnership Act of 2019
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Federal Labor-Management Partnership Act of 2019
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Federal Labor-Management Partnership Act of 2019
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Federal Labor-Management Partnership Act of 2019
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Behavioral Health Crisis Response Improvements Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Behavioral Health Crisis Response Improvements Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Behavioral Health Crisis Response Improvements Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Behavioral Health Crisis Response Improvements Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting drug pricing and the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Prescription Drug Price Transparency Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Prescription Drug Price Transparency Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Prescription Drug Price Transparency Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Prescription Drug Price Transparency Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: SENIOR CARE PHARMACY COALITION · Firm: BGR GOVERNMENT AFFAIRS
Legislation and regulations affecting the long-term care pharmacy industry, S413, HR1316, HR1038
Provide strategic counsel and guidance regarding regulatory policy issues pertaining to CBD in food and beverage.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
APPLIED BIOLOGICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advocate on issues related to Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROLACTA BIOSCIENCE, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to regulation of, access to, and reimbursement for human-milk based exempt formulas
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments that could impact the pharmaceutical and medical device industry generally, and Bayer specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Providing advice, counsel, and services to support the Pharma & Biopharma Outsourcing Association's public policy priorities
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
AMERICAN BEVERAGE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Issues related to beverages in non-alcoholic industry; Supplemental Nutrition Assistance Program; recycling policy and infrastructure; issues pertaining to plastics and plastic waste; federal uniformity for ingredient and labeling standards; tariffs
Issues related to beverages in non-alcoholic industry; Supplemental Nutrition Assistance Program; recycling policy and infrastructure; issues pertaining to plastics and plastic waste; federal uniformity for ingredient and labeling standards; tariffs
Issues related to beverages in non-alcoholic industry; Supplemental Nutrition Assistance Program; recycling policy and infrastructure; issues pertaining to plastics and plastic waste; federal uniformity for ingredient and labeling standards; tariffs
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic advice regarding regulation and coverage of medical devices, including diagnostic tests, in addition to supply chain matters
Filing targets: Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Intl Trade Administration (ITA), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
SENIOR CARE PHARMACY COALITION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEARTLAND FOOD PRODUCTS GROUP via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA (FKA FRESENIUS MEDICAL CARE) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; extension of Medicare sequester; telehealth policy and waivers; issues pertaining to Medicare Secondary Payer Act; oral-only ESRD drugs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE PROCTER & GAMBLE COMPANY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to OTC drug regulation, FDA, FTC, and healthcare policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
REGENERON PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SARGENTO FOODS INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEXCOM via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to Medicare coverage and regulatory policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORCA BIO via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to regulatory and reimbursement policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WK KELLOGG CO (FKA KELLOGG COMPANY) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues related to federal nutrition assistance programs
Filing targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NUVATION BIO INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to FDA policy and treatment of Non-Small Cell Lung Cancer
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
UNILEVER via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DELCATH SYSTEMS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to sustainable reimbursement policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FORS MARSH GROUP via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to federal government contracting
Filing targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
BECTON, DICKINSON AND COMPANY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to medical device regulation, supply chains and trade
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
PEPSICO, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advocate on issues related to the food and beverage industry; SNAP; federal uniformity for ingredient and labeling standards
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
FAIRMOUNT FUNDS MANAGEMENT LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to FDA's regulatory framework for drug-drug combination products and other matters of importance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SARGENTO FOODS INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · RR
Provide strategic counsel and advocate on issues related to H.R.1394/S.184 - Codifying Useful Regulatory Definitions (CURD) Act.
UNILEVER via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Provide strategic counsel and advocate on issues related to food labeling, nutrition standards, tax, tariffs and other matters of importance to Unilever
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FORS MARSH GROUP via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to federal government contracting
Filing targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
WK KELLOGG CO (FKA KELLOGG COMPANY) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues related to federal nutrition assistance programs
Filing targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BECTON, DICKINSON AND COMPANY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to medical device regulation, supply chains and trade
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
STRYKER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to regulations and legislation that could impact the medical device industry generally, and Stryker Corporation specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RECESS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and guidance regarding regulatory policy issues pertaining to CBD in food and beverage.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEPSICO, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advocate on issues related to the food and beverage industry; SNAP; federal uniformity for ingredient and labeling standards
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments that could impact the pharmaceutical and medical device industry generally, and Bayer specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEXCOM via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to Medicare coverage and regulatory policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORCA BIO via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to regulatory and reimbursement policies.
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
NUVATION BIO INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to FDA policy and treatment of Non-Small Cell Lung Cancer
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
DELCATH SYSTEMS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to sustainable reimbursement policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
APPLIED BIOLOGICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advocate on issues related to Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Providing advice, counsel, and services to support the Pharma & Biopharma Outsourcing Association's public policy priorities
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
AMERICAN BEVERAGE ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Issues related to beverages in non-alcoholic industry; Supplemental Nutrition Assistance Program; recycling policy and infrastructure; issues pertaining to plastics and plastic waste; federal uniformity for ingredient and labeling standards; tariffs
Issues related to beverages in non-alcoholic industry; Supplemental Nutrition Assistance Program; recycling policy and infrastructure; issues pertaining to plastics and plastic waste; federal uniformity for ingredient and labeling standards; tariffs
Issues related to beverages in non-alcoholic industry; Supplemental Nutrition Assistance Program; recycling policy and infrastructure; issues pertaining to plastics and plastic waste; federal uniformity for ingredient and labeling standards; tariffs
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic advice regarding regulation and coverage of medical devices, including diagnostic tests
Filing targets: Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Intl Trade Administration (ITA), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
SENIOR CARE PHARMACY COALITION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Legislation and regulations affecting the long-term care pharmacy industry and guidance on H.R. 5031/ S.3159 Preserving Patient Access to Long-Term Care Pharmacies Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FAIRMOUNT FUNDS MANAGEMENT LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to FDA's regulatory framework for drug-drug combination products and other matters of importance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROLACTA BIOSCIENCE, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to regulation of, access to, and reimbursement for human-milk based exempt formulas
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEARTLAND FOOD PRODUCTS GROUP via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
THE PROCTER & GAMBLE COMPANY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to OTC drug regulation, FDA, FTC, and healthcare policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
KRAFT HEINZ COMPANY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to food, recycling, tax, and tariffs; federal uniformity for ingredient and labeling standards
Provide strategic counsel and advocate on issues related to food, recycling, tax, and tariffs; federal uniformity for ingredient and labeling standards
Provide strategic counsel and advocate on issues related to food, recycling, tax, and tariffs; federal uniformity for ingredient and labeling standards
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
REGENERON PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEXCOM via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to Medicare coverage and regulatory policy.
ORCA BIO via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to regulatory and reimbursement policies.
APPLIED BIOLOGICS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Advocate on issues related to Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
RECESS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and guidance regarding regulatory policy issues pertaining to CBD in food and beverage.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide guidance and advocacy with regard to regulations and legislation that could impact the medical device industry generally, and Stryker Corporation specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments that could impact the pharmaceutical and medical device industry generally, and Bayer specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FORS MARSH GROUP via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide strategic counsel and advocate on issues related to federal government contracting
Filing targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
BECTON, DICKINSON AND COMPANY via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to medical device regulation, supply chains and trade
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
NUVATION BIO INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to FDA policy and treatment of Non-Small Cell Lung Cancer
DELCATH SYSTEMS, INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to sustainable reimbursement policy
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FAIRMOUNT FUNDS MANAGEMENT LLC via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to FDA's regulatory framework for drug-drug combination products and other matters of importance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office